---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-24-000328"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:22:05.303552+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1

## Summary
- FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.
- Trial HYPER-H23-1 is a randomized, double-blind, placebo-controlled study of DehydraTECH-CBD in Stage 1 or Stage 2 hypertension.
- Clinical trial commencement is contingent on Lexaria raising sufficient funding.
- FDA review completion marks a key milestone for Lexaria's DehydraTECH-CBD program.

## SEC filing metadata
- accession: 0001640334-24-000328
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000328/0001640334-24-000328-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033424000328/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-24-000328
- JSON: https://secwatch.observer/filing/0001640334-24-000328.json
- Plain text: https://secwatch.observer/filing/0001640334-24-000328.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.